Company news

Genetic Technologies Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Updated Share Consolidation Timetable

December 6, 2023

2023 AGM Presentation

November 21, 2023

Consolidation/Split - GTG

November 21, 2023

Appendix 4C and Quarterly Activities Report - September 2023

October 29, 2023

GTG & Gold Coast Hospital Announce Precision Medicine Pilot

September 27, 2023

MRFF Grant Names GTG as Sole Industry Partner

September 11, 2023

geneType Granted Approval for 3 New Diseases in Australia

September 10, 2023

Annual Results Momentum Building on our Commercial Plans

August 30, 2023

2023 Annual Report and Appendix 4E

August 30, 2023

Updated Investor Presentation - August 2023

August 8, 2023

Appendix 4C and Quarterly Activities Report - June 2023

July 27, 2023

Publication Validates geneType for Melanoma Risk Assessment

April 27, 2023

Appendix 4C & Quarterly Activities Report - March 2023

April 26, 2023

Publication Validates geneType Prostate Cancer Risk Test

April 18, 2023

GeneType MultiTest Panel Expanded Inclusion of New Diseases

March 26, 2023

Further Study Validates geneType Breast Cancer Risk Test

March 12, 2023

Appendix 4D & Half-year Financial Report December 2022

February 26, 2023

Receipt of R&D Tax Incentive Refund for geneType Multi Test

February 16, 2023

Publication Highlights geneType Outperforms Current Models

February 8, 2023

Business Update - February 2023

February 8, 2023

Supplementary Announcement - Comprehensive Risk Test

February 6, 2023

Genetic Technologies Announces US$5M Registered Direct Offer

February 5, 2023

World First Comprehensive Risk Test-Breast & Ovarian Cancer

February 2, 2023

GTG to form Strategic Alliance with global leader QIAGEN

January 31, 2023

Appendix 4C and Quarterly Business Update December 2022

January 30, 2023

Colorectal Cancer Model Presented at ASCOGI Cancer Symposium

January 24, 2023

GeneType Published in PLUS ONE for CVD & Type 2 Diabetes

December 5, 2022

AGM Presentation and Chairmans Address

November 27, 2022

Genetype for Ovarian Cancer published in European Journal

November 9, 2022

GeneType Outperforms Traditional Risk Assessments

September 28, 2022

GTG Building Momentum on Commercial Plans

August 30, 2022

Annual Report to Shareholders and Appendix 4E

August 30, 2022

Q4 FY22 Results Milestones and Growth

July 27, 2022

GeneType Risk Test Implemented in 9 Siles Health Clinics

July 17, 2022

Completion of AffinityDNA Acquisition

July 14, 2022

EasyDNA Expands Indian and European Markets

July 4, 2022

GeneType Risk Assessment Test Onboarding in 16 clinics

June 29, 2022

Transformational Pathway to US Payer System

June 16, 2022

Acquisition of Global Direct to Consumer Ecommerce Business

May 15, 2022

Genetic Technologies 1H FY22 results

February 23, 2022

Half Year Report and Accounts

February 23, 2022

US Patent Office Grants Patent for COVID-19 Risk Test

February 23, 2022

GeneType Multi-Test Approved for Commercial Release

February 20, 2022

Quarterly Activities Report & Appendix 4C

January 18, 2022

Momentum Building with Cash Receipts up 112% for Q2 FY22

December 20, 2021

GTG delivers material increase in cash receipts

October 3, 2021

Presentation to H.C. Wainwright Investment Conference

September 12, 2021

Genetic Technologies FY21 Full Year Results

August 31, 2021

Completion of EasyDNA Acquisition set for global expansion

August 16, 2021

Genetic Technologies Investor Presentation and Webinar

July 27, 2021

← Newer news releases · Older news releases →

Decks

The 5 newest of 55 decks. Every deck is listed under its year.